UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 3, 2020 (March 3, 2020)
EKIMAS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware | | 001-11737 | | 04-3186647 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
95 Washington Street #154, Canton, Massachusetts | | 02021 |
(Address of principal executive offices) | | (Zip Code) |
Issuer’s telephone number (978) 657-0075
ADVANSOURCE BIOMATERIALS CORPORATION
229 Andover Street, Wilmington, Massachusetts 01887
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, par value $0.001 per share | | ASNB | | Not applicable |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On March 3, 2020, EKIMAS Corporation (formerly known as AdvanSource Biomaterials Corporation) (the “Company”), filed a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which provides for a change in the name of the Company from “AdvanSource Biomaterials Corporation” to “EKIMAS Corporation”, effective upon filing. The Certificate of Amendment was unanimously approved by the Company’s Board of Directors. The Certificate of Amendment is attached to this Current Report on Form 8-K as Exhibit 3.1. The description of the Certificate of Amendment herein is qualified in its entirety by the text of Exhibit 3.1 hereto, which is incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EKIMAS CORPORATION |
| |
Dated: April 3, 2020 | /s/ Michael F. Adams |
| Michael F. Adams |
| President and Chief Executive Officer |
